Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to report $5.61 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for ADMA Biologics’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $6.50 million. ADMA Biologics posted sales of $4.73 million during the same quarter last year, which suggests a positive year over year growth rate of 18.6%. The business is expected to report its next quarterly earnings report on Friday, November 2nd.
On average, analysts expect that ADMA Biologics will report full-year sales of $21.03 million for the current year, with estimates ranging from $18.00 million to $22.40 million. For the next fiscal year, analysts expect that the firm will report sales of $55.86 million per share, with estimates ranging from $29.00 million to $111.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover ADMA Biologics.
A number of equities research analysts have recently weighed in on ADMA shares. ValuEngine upgraded ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Chardan Capital started coverage on ADMA Biologics in a report on Monday, July 30th. They issued a “buy” rating and a $10.00 price objective for the company. Maxim Group set a $10.00 price objective on ADMA Biologics and gave the company a “buy” rating in a report on Monday, May 14th. Oppenheimer started coverage on ADMA Biologics in a report on Thursday, July 12th. They issued a “buy” rating and a $13.00 price objective for the company. Finally, BidaskClub downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Seven investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $9.50.
In related news, CEO Adam S. Grossman acquired 52,301 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was acquired at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the acquisition, the chief executive officer now owns 32,527 shares of the company’s stock, valued at approximately $155,479.06. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman acquired 20,921 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, with a total value of $100,002.38. Following the acquisition, the director now directly owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. Insiders purchased 78,222 shares of company stock valued at $373,901 in the last quarter. 16.90% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Millennium Management LLC increased its holdings in ADMA Biologics by 254.0% in the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 48,455 shares during the last quarter. BlackRock Inc. increased its holdings in shares of ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 15,115 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of ADMA Biologics in the first quarter worth about $102,000. JPMorgan Chase & Co. bought a new stake in shares of ADMA Biologics in the first quarter worth about $182,000. Finally, Element Capital Management LLC bought a new stake in shares of ADMA Biologics in the first quarter worth about $118,000. Institutional investors and hedge funds own 56.38% of the company’s stock.
ADMA stock opened at $6.85 on Thursday. The firm has a market cap of $296.17 million, a PE ratio of -3.59 and a beta of 2.36. ADMA Biologics has a twelve month low of $2.01 and a twelve month high of $6.93. The company has a quick ratio of 8.88, a current ratio of 10.65 and a debt-to-equity ratio of 0.79.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.